Objective. Based on the results of two recently published, randomized, double-blind and placebo-controlled studies, a possible improvement in rheumatoid arthritis disease activity after oral tolerization with triple helical collagen type II has been suggested. The goal of this study was to go one step further and ask the question whether collagen type II can sustain the therapeutic effect induced by methotrexate, the most widely accepted disease-modifying anti-rheumatic drug in patients with long-standing rheumatoid arthritis.
O of the primary goals in developing effective [8] , COL II has been chosen as an oral toleragen in therapy for autoimmune diseases is to suppress autoclinical trials on patients with RA. There is no convinreactive immune processes specifically without affectcing evidence that COL II itself is the relevant mediator ing the remainder of the immune system. Short-term of disease activity in RA, but antigen-specific bystander studies and meta-analyses have repeatedly proven the suppression has been discussed in several animal efficacy of disease-modifying anti-rheumatic drugs models as a mechanism of oral tolerance, where the (DMARDs), but many patients take them for <5 yr antigen used is not responsible for the chronic immune because of either lack of efficacy or toxic effects [1] .
response in the target organ [7, 9] . Regarding methotrexate (MTX ), one of the most Based on these rationales, Trentham et al.
[10] widely used DMARDs in rheumatoid arthritis (RA), performed a first placebo-controlled double-blind only 30% of patients in a large cohort were taking it study with COL II from normal chickens in 60 patients for >10 yr, and 50% discontinued it due to toxicity [2] .
with active RA in 1993. A significant improvement in Oral tolerance therapy has long been recognized as painful and swollen joints could be shown in the being able to induce peripheral immune tolerance to patient group receiving collagen. In a second, placebospecific antigens [3] and has been examined in animal controlled study in patients with early RA conducted studies [4] . Oral administration of pepsin-digested, by Sieper et al. [11] , bovine COL II was given in triple helical collagen type II (COL II ) has proved higher doses (1 and 10 mg/day, respectively). Only a highly effective in various animal models of human slightly higher (but non-significant) response rate autoimmune diseases, including collagen-induced arthamong COL II-treated patients compared to placebo ritis [5, 6 ] and adjuvant arthritis [7] . Because of some could be demonstrated. similarities of these animal models to RA, and con-
The rationale of the present study was to apply sidering the abundance of COL II in articular cartilage several parameters used in the first controlled study by [12] who were on an ongoing
Concomitant medication Doses of NSAIDs and glucocorticosteroids were and unchanged treatment for at least 8 weeks with MTX as the only DMARD, presenting an RA funckept constant for the entire trial period. A change in glucocorticosteroid dose as well as intra-articular or tional status of class I-III according to the ACR criteria [13] , and who were on an unchanged dose i.m. injections of glucocorticosteroids during the study were considered a protocol violation leading to terof glucocorticosteroids of ∏12.5 mg/day and of nonsteroidal anti-inflammatory drugs (NSAIDs) within mination of the study. In the case of an exacerbation of disease activity, an augmentation of NSAIDs to the last 2 weeks before starting the study, were eligible for participation and included after written informed maximal recommended doses and additional paracetamol up to 4 g/day was allowed as escape medication. consent by the patient.
Patients were excluded from the study if <18 yr of age and in the case of intra-articular glucocortico-
Data collection and measures
For all patients, three study visits were determined steroid use within 3 weeks before entering the study.
(day 0, 30 days and 90 days after enrolment) and examination performed by the same clinical investig-
Study design and treatment
Patients were randomly assigned in a double-blind ator, who was unaware of the treatment group assignments. fashion to receive either COL II or MTX for 3 months. The minimal sample size n was 40 patients per treatPatient characteristics (Table I) ( Table I ) . COL II. Collagen type II was isolated (PB) by limited pepsin digestion of sternal cartilage from comNew radiographs of both hands and feet were reviewed in a blinded manner for the presence or mercial 40-day-old male broiler chickens. The protein was purified as published earlier [15] . The purity of absence of RA-related erosions.
The following clinical disease variables were assessed the protein was judged by gel electrophoresis and exclusively produced bands corresponding to polypepat each study visit. Primary endpoints. Disease activity as assessed by tides of COL II were the accepted standard. After purification, the protein was dissolved in 0.1  acetic the physician (number of tender and swollen joints out of 28 joints). In addition, disease activity was calculated acid and solutions containing 0.5 mg of COL II were mixed with 120 ml of heat-inactivated orange juice, using the number of tender and swollen joints, and ESR by applying the algorithm of the disease activity containing 0.15% sodium benzoate (stabilizer). The volume was filled in tetra packages and stored until score [20] [21] [22] [23] [24] as assessed by the physician (DAS) and the patient (RA disease activity index, RADAI ) use at 4-8°C. During the study, all patients stored their collagen at the same temperature throughout the [25-27]. In both scores (DAS and RADAI ), the value of 10 is the highest possible disease activity. whole study period.
Chicken COL II was purified identically as reported Seven secondary endpoints.
(1) Other clinical parameters of disease activity including morning stiffness by the group of Trentham [10] . Even if bovine COL II has a higher homology to human COL II, we decided [24, 25] , grip strength on both sides with use of a Martin vigorimeter, and muscle strength [28] as to use the chicken species for two reasons. Seattle, WA, USA).
* ± values are means ± .. There is no significant difference RESULTS (P ∏ 0.05) between the two treatment groups.
Baseline characteristics †ACR functional status of rheumatoid arthritis [13] .
Ninety-two patients on an established therapy with ‡DAS, validated Disease Activity Index, using a maximum joint count of 28 (tender and swollen) in addition to ESR (see Patients MTX were randomly assigned to receive daily 0.5 mg and methods).
COL II (46 patients) or an unchanged dose of MTX §HLA-DRB1*0101, 0401, 0404, 0405, 0408, 1402 (see Patients (46 patients). There were no significant differences in and methods).
baseline characteristics among the groups at study entry ( Table I ) . and the patient [Health Assessment Questionnaire (HAQ), a score of 3 indicating greatest disability]
Treatment-related disease activity and short-term outcome measures [29] [30] [31] . (4) Health-related quality of life, as assessed by the patient (SF-36 mental and physical component Table II shows the mean values and .. of disease activity (five variables) and of disease outcome (three score questionnaire, a score of 100 being the best possible value) [32] [33] [34] . (5) Assessment of general variables) as assessed by the physician and by patients at baseline and after 1 and 3 months of therapy. After health by the physician and the patient on a numerical rating scale 0-10. (6) Overall assessment of the efficacy 3 months of therapy, there were significant differences in changes in four of five variables with respect to and tolerability of the drug by the patient and the physician on a five-point rating scale. (7) Increase in disease activity and in two of three variables with respect to disease outcome between the patient group dose of NSAIDs as escape medication.
Case conclusion (successful termination or discontinureceiving COL II and the MTX group. Most impressive, after 3 months, the mean swollen ation of study). Case conclusion of each patient was classified and recorded either as regular termination of joint count of the COL II group was 9.02 compared to 5.91 in the group receiving MTX, denoting a the study or premature discontinuation with subsequent registration of exact study duration and significant absolute difference in 3.68 swollen joints between the two groups with respect to their baseline specific reason for drop-out. Each patient who dropped out had a final clinical and laboratory examination values (15% improvement in the MTX group vs 41.2% deterioration in the COL II group). Lower, but still and a set of questionnaires (HAQ, RADAI, SF-36) to answer within 2 days after drop-out.
significant differences in mean changes between these two treatment groups could already be seen after 1 Monitoring for adverse events. To monitor for safety and possible adverse events, the following variables month. Regarding the ESR, the absolute difference in the mean changes between the two groups from their were investigated at each visit in addition to questioning about the presence, frequency, duration and baseline values was 14 mm (5.5% decrease in the MTX group vs 60.4% increase in the COL II group). After intensity of adverse events: clinical status and complete *± values are means ± .. †Joint scores and other assessment variables are described in Patients and methods. Baseline visit at study day 0, second visit at study day 30 and third regular visit at day 90 or after drop-out between day 30 and 90. All patients who had at least two study visits (day 0, and between day 0 and day 30) were included in the analysis of variables at day 30. All patients who had a third study visit between day 30 and day 90 (all patients including regular termination and drop-out) were considered for the analysis of variables at day 90 (intention-totreat analysis).
‡P values of each variable shown at baseline are for individual comparisons of variables. P values of variables of disease activity, and outcomes between different treatment groups after 1 and 3 months, are based on absolute changes from baseline within each treatment group.
3 months, the mean difference in the DAS between the (SF-36, physical component score) between the two groups were 7.4 units on a scale of 100 units with two groups was 0.89 units on a scale from 0 to 10 (4.4% decrease in the MTX group vs 16.5% increase respect to their change from baseline values. All variables of disease activity and short-term disease outin the COL II group with respect to their baseline values), and is clearly higher than the minimal required comes in the treatment group receiving MTX were constant over time and did not show any significant change of 0.6. In contrast, the patient-assessed RADAI was not different between the two groups.
changes during the study. After 3 months of treatment, very similar and highly After 3 months, the physical functional status (HAQ), a patient-oriented disease outcome measure, significant differences in changes in other variables of disease activity (morning stiffness, P = 0.0031; CRP, also showed a significant difference in change from their baseline values between the two groups (0.36 P = 0.0004), symptom severity (pain, P = 0.0005), functional impairment (muscle strength index, units on a scale from 0 to 3). Absolute and relative differences concerning the health-related quality of life P = 0.014) and of an overall assessment of the treat- Swollen joints (0-28) (after 3 months) P = 0.01 ‡ P < 0.0001 Tender joints (0-28) (after 3 months) P = 0.63 P = 0.31 Erythrocyte sedimentation rate (mm/1 h) (after 3 months) P = 0.54 P < 0.0001 F. 1.-Kaplan-Meier curve showing highly significant differences between the number of successful completers (patients remaining in *After a study duration of 3 months, only 75 of the initial 92 the study for 90 days according to their assigned treatment) in the patients were available for evaluation (see Table IIa) .
two treatment groups. There are 85% successful completers in †Stratification of patients according to disease duration was the group receiving methotrexate (39/46) compared with 43% in the performed post hoc.
group receiving collagen type II (20/46) (P < 0.0001). The numbers ‡P values were calculated using the Mann-Whitney U-test.
of patients actively participating at the three study visits (day 0, day 30 and 90) per treatment group are shown below the graph. For details of statistical evaluation, see Patients and methods. subanalysis of patients with a disease duration of <5 yr ( Table IIb) all patients of the two treatment groups (Table IIa) , no or only weak statistically significant differences between COL II-and MTX-treated patients after 3 ment at the end of the study by patients (P < 0.0001) months could be demonstrated in patients with a and the physician (P < 0.0001) could be shown disease duration of <5 yr with respect to disease between the treatment groups receiving MTX and the activity. Moreover, in this subgroup, not only 94% of group receiving COL II (data not shown). Moreover, MTX patients, but also 94% of the patients receiving patients under MTX did not increase their dosage of COL II, concluded the 90 study days successfully, NSAIDs and paracetamol as escape medication more compared to only 32% of COL II patients with a frequently than collagen patients (data not shown). On disease duration of Á5 yr. the contrary, between study weeks 3 and 6, patients in Study subanalysis of patients with a disease duration the MTX groups used significantly less paracetamol of <2 yr was not possible due to the very small sample than patients in the COL II group. size of only six out of 92 patients.
Case conclusion (discontinuation or successful Adverse events termination of the study)
There were no significant differences in the frequency Overall, 33 patients (35.9%) discontinued the study of adverse events between the two treatment groups, ( Table III ) . The remaining 59 patients completed the as shown in Table IV . The same was true for the study successfully. The significant differences in treatduration and intensity of adverse events (data not ment-related disease activity and disease outcome are shown). Adverse events included nausea and augreflected by the Kaplan-Meier curve, showing highly mented loss of hair in patients on MTX, and heartburn significant differences between the number of successful and slight stomach ache in patients with COL II. No completers (85% successful completers in the group serious adverse events were recorded during the receiving MTX vs 43% in the group receiving COL II, P < 0.0001) ( Fig. 1) .
entire trial. tion of the effect of oral COL II, induced by the ‡Differences between the two groups were calculated using the withdrawal of MTX in our patients at the beginning x2 test.
of the study (possibly a shift of T cells into a Th1 direction), cannot be excluded.
Although it does not come as a great surprise that DISCUSSION patients randomized to COL II did worse than patients remaining on MTX, our comparative study could This randomized controlled trial over 3 months in 92 patients with active, long-standing RA demonstrates clearly demonstrate the limitations of COL II in patients with long-standing RA under stable therapy a highly significant increase in disease activity and significant deterioration of short-term disease outwith MTX. However, due to the design and the average disease duration of our patients with RA, we do not comes under a treatment with 0.5 mg daily of orally administered COL II from chicken as compared to a provide data on the effect of oral COL II in comparison to placebo in early RA. continuously given unchanged therapy with MTX. Although the absolute changes in the parameters of We did not follow up all patients systematically, but the patients who were controlled by the out-patient disease activity and outcome are not dramatic, the difference in their relative change from baseline was clinic at the department of rheumatology of the University Hospital regained all their previous benefit between 60 and 15%, and therefore in part highly significant. The differences in the mean changes in from MTX after recommencing this therapy.
Sieper et al. [11] suggested in their study an identicertain parameters from baseline between the two groups were clearly higher than the assumption made fication of patients with a good response to COL II therapy. The groups in that publication had a much to determine the primary endpoint (30% difference in swollen joint count between the two groups) in order shorter disease duration, namely <3 yr. A post hoc analysis of our data revealed the interesting finding to power the study and determine sample size.
A significantly larger number of patients disconthat in patients with a disease duration of <5 yr, COL II could sustain an MTX-induced therapeutic tinued the study in the collagen treatment group as compared to the MTX group due to a lack of sustaining effect on disease activity better than in patients with a longer disease duration. In addition, 94% of the the former MTX-induced anti-inflammatory effect. Since an increase in dose of NSAIDs to maximal patients with a shorter disease duration completed the study successfully as compared with only 32% who recommended doses and an additional maximal dose of paracetamol up to 4 g was allowed as escape medicahad a disease duration of Á5 yr. Owing to the smaller number of patients in this subgroup analysis and the tion, it is reassuring to know that patients on MTX did not increase their dose of these two medications post hoc stratification, a log rank test was not performed between the two groups with different disease more frequently than collagen patients.
While patient characteristics, pre-existing duration. Several questions remain to be answered concerning DMARDs, preparation and dose of COL II between the study of Trentham et al.
[10] and our study were the therapeutic concept of oral tolerization. What are the optimal doses of orally administered COL II? almost identical, two important differences are worth noting: first, intra-articular corticosteroids were not Which patients with autoimmune diseases, if any, profit most from it? Ongoing studies and future trials have allowed as escape medication during our study and, second, our collagen dose was 0.5 mg as compared to to address these questions in order to clarify further the potential role and effectiveness of COL II as a 0.1 mg used by Trentham et al. during the first month. Both factors might, in part, explain the differences in toleragen in RA. efficacy and premature drop-outs between COL II-A treated patients in the two studies. The disease of our patients receiving COL II, regarding the average We are indebted to the Deutsche Gelatine Fabriken Stoess AG, Eberbach, Germany, Wyeth-Lederle, Zug, number of swollen and tender joints ( Table IIa) , was probably more active compared to the patients in the Switzerland, and Bristol Myers, Baar, Switzerland, for
